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Abstract
The benefit for patients with operable breast cancer treated with adjuvant systemic therapy is small,
if reduction of early mortality within the context of randomized control trials is used for treatment com-
parison. One might consider that the 75%-85% of patients who die despite treatment are overtreated,
as are patients who remain alive even without therapy within a given time frame. Larger treatment benefits
in terms of avoided or delayed breast cancer relapse have been demonstrated even at early phases
of follow-up in the vast majority of adjuvant trials. Exposure of all patients to adjuvant therapy at a time
at which no symptoms of disease are present is detrimental in terms of quality of life.
Based on our assumption that the quality of life of the patient is typically altered both by subjective
toxic effects of adjuvant treatment and by the appearance of relapse, we developed a method of com-
paring treatment effects in terms of time without symptoms of disease and toxicity of treatment (TWiST).
Because the impact of treatment on relapse rates appears earlier than survival effects in all adjuvant
therapy trials, and because the value of time without relapse in terms of the quality of life of the patients
is as yet poorly defined, we have generalized our method of comparing treatment attitudes to include
individual qualitative judgment values. The experience gained from integrating quality-of-life issues
into clinical trials for breast cancer might also be applied to other diseases characterized by a chronic
course, toxic treatments, and gains in periods of relative or absolute freedom from toxic effects and
progressive disease.
INTRODUCTION
Most patients with operable breast cancer relapse and die of the disease. The annual
relapse rate is relatively small and is related to many prognostic indicators which de-
We thank our colleagues Drs. R. J. Simes, P. Glasziou, and A. Coates for their significant contributions
to developing the methodology.
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pend upon biological factors. Even for patients with metastases in axillary nodes, the
annual relapse rate is about 10% per year. The annual mortality rate for this popula-
tion is about 5% per year (12). Improvements in outcome include a significant reduc-
tion of relapses seen in most of the individual trials (11) and a 15%-25% reduction
in the odds of death within 5 years. An overview combining data from all available
relevant randomized trials was required to demonstrate the presence of these treat-
ment effects statistically (13). The considerable efforts being made presently to im-
prove these results include, among others, investigation of the ideal timing for adminis-
tration of adjuvant therapy, evaluation of intensive treatment regimens which require
autologous bone marrow transplantation, use of recombinant colony-stimulating factors
to reduce marrow toxicity, and study of hormonal agents used in association with che-
motherapy. It is unlikely, however, that a definitive breakthrough will be achieved by
these approaches, and it might be anticipated that advances in the treatment of oper-
able breast cancer in terms of overall survival improvement will continue to be of small
magnitude.
Such a prospect underscores the need for alternative evaluation methods which
take into account the well-being of the patients. The following facts might be consid-
ered:
1. There is an increased tendency to treat patients with node-negative disease (1;7),
whose risk for relapse is smaller than that of women with node-positive disease (for
whom the value of systemic adjuvant therapy has been established during the past
2 decades).
2. Many physicians are more aware of issues of quality of life. An increasing number
of health care professionals understand that the simplistic approach to cancer treat-
ment, "better to live more decently even if for a shorter period," represents a logical
error: "shorter" in most cases rs related to "worse" in advanced disease (4) and prob-
ably also in the adjuvant setting (6).
3. Adapting treatment results from clinical trials to the individual patient situa-
tion is very difficult and requires certain assumptions, a number of which are derived
empirically. This, of course, is acceptable, since many aspects of modern medicine re-
late to empirical experience. It can very easily become a matter of controversy, how-
ever, especially if the treatment results in terms of disease control are of modest mag-
nitude and borderline significance, while the side effects and costs of treatment are
acute and obvious.
Additional endpoints that take into account factors related to the well-being of
the patients represent an obviously important tool for decision-making when the
treatment-choice situation is such as that currently applying for operable breast cancer.
DEVELOPMENT OF COMPARISON METHODS
TWiST Methodology
In 1986 (6), we described the TWiST methodology, which was applied to a data set,
including 463 postmenopausal patients with N+ breast cancer who were randomized
into Ludwig Trial III to receive either a chemoendocrine therapy (cyclophosphamide,
methotrexate, 5-fluorouracil, prednisone and tamoxifen; CMFp+T) for 1 year or
endocrine therapy alone (p+T) for one year or no adjuvant therapy (Observation).
The time without symptoms of disease and toxic effects of treatment (TWiST) was
considered as the endpoint. Its construction was based upon definitions which are sum-
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Table 1. Definition of Quality-of-Life-Oriented Endpoints
Event Abbreviation Time assigned to
Any reversible subjective toxic TOX
effecta of any grade (excluding
amenorrhea) reported during a
cycle or month of treatment
Alopecia and weight gain TOX
Isolated mastectomy scar or LRb
contralateral breast cancer alone
Any relapsec (other than LR) or REL
second primary tumour (not
breast)
Leukopenia, thrombocytopenia,
and grade 1 or 2 anemia
(asymptomatic)
None of the above TWiST
Applied to the entire month
Include an additional 3 months
after last report to allow for
recovery
Assign 3 months to allow for
recovery from local treatment
Applies to entire remaining
survival period
No penalty
Applies to any remaining
survival time
a
 Subjective toxic effects include those noted and graded by the investigators: nausea, vomiting, anorex-
ia, diarrhea, mucositis, infections, epigastric pain, neurotoxicity, headache, euphoria, depression, al-
lergic skin disorders, alopecia, cystitis, muscle weakness, hypercalcemia, hot flashes, thrombosis,
thromboembolism, edema, lymphedema, weight gain, eye disorders, joint pain, symptomatic anemia,
hemorrhage, nonmenstrual vaginal bleeding.
b
 For convenience, this 3-month period has been incorporated within REL in the analysis.
c
 Skeletal recurrences were considered only at the time of definitive confirmation.
marized in Table 1. TWiST was calculated by subtracting from overall survival all time
periods for which some subjective toxicity (TOX) was noted, and all time following
symptomatic systemic relapse (REL) that involved treatment intervention. In addition,
an isolated mastectomy scar recurrence or contralateral breast cancer alone (LR) was
considered separately. This pragmatic approach has been the basis for the develop-
ment of the methodology, but it could hardly be considered an accurate way to evaluate
the actual impact of treatment felt by the patients. Life with subjective toxicity and
with some symptoms of relapse are obviously far from optimal conditions of life, but
most women with breast cancer will, nevertheless, consider these periods to have some
value greater than death (3).
Q-TWiST Methodology
In order to allocate some value greater than zero to time periods during which the
patient is alive with or without the occurrence of a quality of life related event, the
following considerations were made (using the same criteria as for the TWiST method).
The time period with subjective toxic effects (TOX) is a period of time for which
the perception of well-being of the patients has a large spectrum of values. In fact,
many patients are encouraged to be very active (i.e., choose toxic adjuvant therapy
if this is an option) and accept with philosophy the subjective side effects associated
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Figure 1. Calculation of quality-adjusted survival relative to TWiST (Q-TWiST):
Weighted summation of time periods TOX, TWiST, and REL. Utility coefficients of
u, = 0.75 for TOX and ur = 0.50 for REL are illustrated.
with adjuvant treatment. This attitude relates to the insurance mentality: invest now
(in toxicity) to slightly reduce a heavy risk later. On the other hand, many patients
are anxious to return to normal life as soon as possible after facing the initial diagnosis
of breast cancer. This is typically obtained with various degrees of denial, a mecha-
nism that is easily disturbed by adjuvant treatment.
The time following systemic relapse (REL) is shaded by the fact itself of recon-
fronting the disease. The need for palliation is dependent upon the manifestations of
the relapse and is common. Furthermore, the almost universally fatal outcome reduces
the spectrum of perceptions as compared with the range that is applicable to TOX.
The possibility to incorporate these concepts within the framework of the TWiST
methodology is provided by introducing the notion of utility coefficients.
Quality-adjusted survival analysis is performed by considering utility coefficients
u, and ur, taking values between 0 and 1, to represent the value, relative to TWiST,
of toxic periods (TOX) and time after relapse (REL), respectively. Quality-adjusted
survival relative to TWiST (Q-TWiST) for a patient who experiences an overall sur-
vival composed of TOX, TWiST, and REL is calculated as
Q-TWiST = u, x TOX + TWiST + ur X REL.
Figure 1 illustrates the way in which u, and ur influence the addition of time
periods to the "baseline" TWiST for arbitrarily chosen values of 0.75 for u, and 0.50
for ur.
Population estimates of Q-TWiST achieved for a specific treatment regimen are
obtained by partitioning overall survival up to a specified time from randomization
into three regions (see Figures 2A-C). The regions are distinguished by curves for du-
ration of toxic effects, time to systemic relapse, and overall survival time. The average
amounts of time spent in TOX, TWiST, and REL for each treatment group up to a
specified cut-off time from randomization are estimated by the areas between the curves,
as shown. These averages are then combined as a weighted sum according to the above
equation to obtain an average Q-TWiST for each treatment.
The average times accumulated in TOX, TWiST and REL during 7 years, which
are graphically presented in Figure 2, may also be described numerically as shown in
Table 2. The calculation of Q-TWiST is illustrated by a weighted combination of these
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Figure 2. Time accumulated up to 7 years from randomization in Ludwig Trial III
example. Time is partitioned for each treatment group by curves for time with toxicity,
time to systemic relapse, and overall survival. Areas between these curves yield popula-
tion average values for TOX, TWiST, and REL. Panel A = CMFp+T, panel B =
p+T, and panel C = observation.
405
terms of use, available at https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0266462300007467
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 11:33:54, subject to the Cambridge Core
406 GELBER AND GOLDHIRSCH
Table 2. Components of Q-TWiST for Treatment Evaluated in Ludwig Trial
TOX
TWiST
REL
Q-TWiST
(u, = ur = 0.5)
CMFp + T
9.6 (0.4)
50.3 (2.5)
7.1 (1.1)
58.7 (2.2)
P + T
2.0 (0.3)
47.1 (2.7)
12.9(1.4)
54.6 (2.3)
Observation
0.0 (0.0)
41.5 (2.6)
20.9(1.8)
51.9(2.2)
Note: Average months of TOX, TWiST and REL accumulated within 7 years of randomization, with
Q-TWiST calculated for arbitrary utility coefficients (u/ = ur = 0.5). (Standard errors are shown in paren-
theses.)
CMFp + T = cyclophosphamide, methotrexate, 5-fluorouracil, prednisone + tamoxifen (chemoendo-
crine therapy) given for 12 months.
p + T = prednisone + tamoxifen (endocrine therapy alone) given for 12 months.
Observation = no adjuvant therapy
0.8
0.6
0.4
0.2
n
SDFS
CMFp+T
Survival
/
/o
TWiST
0.2 0.4 0.6 0.8
Figure 3. Threshold analysis for Ludwig Trial III comparing average Q-TWiST values
accumulated up to 7 years from randomization. Lines are drawn for values of u, and
ur which yield equal values of average Q-TWiST between treatment pairs.
components using «, = ur = 0.50. Based on these arbitrary values for the utility
coefficients, the average Q-TWiST accumulated during 7 years (84 maximum possible
months) for chemoendocrine therapy was 58.7 months —4.1 months longer than for
endocrine therapy alone (p = 0.20) and 6.7 months longer than for the observation
group (/? = 0.05).
In order to avoid relying on arbitrary selection of specific values of ut and ur,
treatment comparisons can be made using a threshold analysis. The methodology is
described in greater detail in a recent publication (8). Threshold values of u, and ur
between treatment pairs are those for which the treatments have equal average Q-TWiST
values. Figure 3 shows the threshold analysis for Ludwig Trial III with cut-off at 7
years from randomization. The bold lines divide the figures into three regions where
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each treatment is favored according to the values placed on time with toxicity (u,) and
time following systemic relapse (ur) relative to TWiST. The dashed lines show the
thresholds between pairs of treatments. For the specific values at the corners of Figure
3, treatment comparisons are for systemic-disease-free survival (ut = 1, ur = 0),
TWiST (u, = 0, ur = 0), and overall survival (u, = 1, ur = 1). The threshold analysis
for our specific example indicates that CMFp+T is the preferred treatment for a wide
range of plausible values of u, and ur. It is important to note that these thresholds
are based upon 7-year figures, and further follow-up might change the relative Q-TWiST
values associated with the three treatment options.
In order to provide some data about the statistical uncertainty of the results, we
display the threshold lines together with their confidence intervals. The comparisons
of CMFp+T versus Observation (Figure 4A) and CMFp+T versus p+T (Figure 4B)
are shown. For the first comparison, there is a statistically significant difference in
favor of CMFp+T for most values of u, and ur. The confidence regions for CMFp+T
versus p+T are wide, and the range of values of ut and ur, for which the chemoendo-
crine therapy is statistically significantly preferred, is small.
The chemoendocrine therapy involves early toxicity but later gains, which exceed
those of the endocrine therapy alone. The evolution of the differences in average Q-
TWiST (for u, = ur = 0.5) between treated and control groups is displayed in Figure
5A. As time from randomization increases, the early losses caused by toxic effects are
counterbalanced by the gains associated with delayed relapse, so that an average overall
gain for the population of treated patients begins to emerge at 3-4 years after opera-
tion. The evolution of results for other endpoints of TWiST (Figure 5B) and overall
survival (Figure 5C) can be displayed in similar fashion. This practice of displaying
the results in terms of different endpoints illustrates the clinical utility of the methods,
since the dimension of time from diagnosis (or from primary treatment) is added for
comparison with the conventional assessments of disease-free survival and overall sur-
vival.
It is important to note that the treatment comparisons displayed in Table 2 and
Figures 2-5 are based upon the specific data available from Ludwig Trial III. The en-
docrine therapy was given for the duration of 1 year only, a suboptimal use of this
treatment modality. Standard chemotherapy regimens of today include 6 months of
cytotoxics and not the 1 year used in our example. Other forms of adjuvant therapy
or prolonged duration of tamoxifen might improve both the length and quality of life
compared with the 12-month CMFp+T regimen.
Adding Other Arbitrary Utility Coefficients to Q-TWiST
Some other ideas related to economical sciences may be borrowed for our attempt
to integrate quality-of-life-oriented values to the analysis of breast cancer therapies.
One year commencing from the present time might have intrinsically more value than
1 year commencing from some time (5 years, say) in the future. A discount rate per
year of life without relapse may be considered to express the fact that the loss of present
time because of immediate toxicity might be too high a price for gaining an equal
amount of time in the future. Similarly, delaying a relapse that would have occurred
late might not be as valuable as delaying an early recurrence. A delayed relapse also
has a better prognosis (9) in terms of survival, and, therefore, some kind of discount
might be justified.
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Figure 4. Pairwise treatment comparisons for (A) CMFp+T versus Observation and
(B) CMFp+T versus p+T showing 80% and 95% confidence regions.
Criticism may obviously be raised against this discounting policy because of the
fact that many patients might reason according to the "insurance mentality"—an invest-
ment today (in terms of toxic effects to all) for a chance of reduction of odds of relapse
in the future should not be penalized regardless of when the relapse eventually occurs.
It is important to evaluate the prospective perception of the patient regarding a delayed
relapse, whether early or late. The effect of the discounting of time by 10% per year
on our Ludwig Trial III example within 7 years is displayed in the threshold analysis
presented in Figure 6. As expected, if later gains are assigned lower values, early toxic
effects of adjuvant therapy are more difficult to justify.
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Figure 5. Treatment differences relative to observation as functions of time from ran-
domization. Differences are in terms of average months of Q-TWiST accumulated since
randomization for (A) Q-TWiST with arbitrary values u, = ur = 0.5; (B) TWiST (i.e.,
Q-TWiST with u, = ur = 0); (C) overall survival (i.e., Q-TWiST with u, = ur = 1).
But What is the Single Answer Provided by a Q-TWiST Analysis?
Four values must be specified in order to obtain a unique solution for average Q-TWiST
treatment comparisons derived from a clinical trial data set: the two utility coefficients
u, and ur, the time from diagnosis considered for the comparison, and the discount
factor. Some might be uncomfortable with the prospect that a clinical trial not yield
a definitive answer recommending a treatment for application to all patients. Yet, quality
of life is a philosophical issue that in fact cannot have such a unique answer. The
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Figure 6. Threshold analysis for Ludwig Trial III within 7 years from randomization
with the value of future time discounted at 10% per year.
Q-TWiST methodology is developed with this spirit, recognizing that choices are re-
quired to be individualized and establishing a framework within which the parameters
for treatment choice can be explicitly introduced.
Specifically, consider the choice of ut and ur, the utility coefficients associated
with time in toxicity and time after relapse. Using the threshold analyses displayed
in Figure 3, one can determine the values of u, and ur for which the chemoendocrine
therapy is preferred to either of the other two treatment options. If, based on subjec-
tive feelings, toxic effects are not considered to be too debilitating compared with the
impact on quality of life of a systemic relapse, then u, is higher than ur and the data
in this example favor chemoendocrine therapy. Note that the subjective feelings of rel-
ative worth might be derived from the physician (motivated by a prejudice to treat
or not to treat), and/or by the patient (who clearly expresses a preference relating to
her personal life status at the time).
In fact, given that a particular treatment choice is made (e.g., use chemoendocrine
therapy for one year rather than no adjuvant treatment), the threshold analysis in Figure
3 defines the implicit relative values of u, and ur that apply. In this way the prejudices
of physicians who choose a particular treatment strategy are described in terms of how
they must weigh the relative value of the time periods TOX, TWiST, and REL.
The other two variables (time from diagnosis and discount rate) are easier to handle.
The time from diagnosis is constrained by the maturity of the data set. In order to
consider results that are less subject to statistical fluctuations, we generally extrapo-
late no further than the median follow-up of the study cohort. The choice of discount
factor is related to the patient's age, family situation at the time of diagnosis, and the
relative value of the next year as compared with a year that is several years into the
future. A time trade-off methodology might be useful for determining the discount
rate. The exact specification of the discount rate is, however, not crucial for the appli-
cation of the methodology because even with a discount of 10% per year (about 40%
terms of use, available at https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0266462300007467
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 11:33:54, subject to the Cambridge Core
COMPARISON OF ADJUVANT THERAPIES 411
INTERNATIONAL BREftST CANCER TRIAL VI
PRE- AND PERIMENOPAUSAL PATIENTS WITH
OPERABLE NODE-POSITIVE BREAST CANCER
STRATIFY
surgery
ER status
institution
R
A
N
D
0
M
I
Z
E
A) I I I I I I
B) I I I I II
O I I I
D ) I I I I
1 2 3 4 5 6
CMF x 6
| C M F x 6 + 3 x C M F x l
CMF x 3
C M F x 3 + 3 x C M F x l
12 15 MONTHS
INTERNATIONAL BREAST CANCER TRIAL VII
POSTMENOPAUSAL PATIENTS WITH
OPERABLE NODE-POSITIVE BREAST CANCER
STRATIFY
surgery
ER status
institution
R
A
N
D
0
M
I
Z
E
Oral CMF
C - cyclophosphamide
M - methotrexate
F - 5-fluorouracil
E)
F)
G)
H)
l - l - l -
l - l - l -
1 2 3
-> TAM x 3 yrs
|> TAM + 3 x CMF x 1
-> TAM + CMF X 3
- I > TAM + CMF X 3
+ 3 x CMF X 1
12 15 MONTHS
100 mg/m ora l ly days 1-14 |
40 mg/m i . v . days 1 and 8 |
.2
-q 28 days
600 mg/m* i . v . days 1 and 8 |
TAM - tamoxifen 20 mg dai ly for 3+ years
Figure 7. Designs for International Breast Cancer Study Group (IBCSG) Trials VI
and VII: Adjuvant therapy for women with operable node-positive breast cancer.
over a cumulative 5-year period), conclusions are not much altered from a zero dis-
count analysis.
The importance of the analysis is to recognize its subjective nature and explicitly
define the parameters that impact upon treatment choice. Integrating individual pa-
tient perceptions into the analysis of treatment choice is the next logical step to in-
crease the clinical application of the methodologic framework.
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Integrating Perceptions and Opinions of Individual Patients
into the Analysis of Treatment Results
The development of the TWiST and Q-TWiST methodologies was based upon the
perception and biases of physicians as to the values of life periods. The direct possi-
bility to integrate the patients' own value judgments into the analysis was not possible
because of the lack of prospectively collected information. The idea, however, has ma-
tured rather early during the developmental process, and some instruments are being
used in recent trials of systemic adjuvant therapy. The objective is to assess patient
coping, well-being, and subjective burden of some toxicities to obtain relative values
for TOX, TWiST, and REL directly from the population of study patients. The trials
in which these instruments are being tested are outlined in Figure 7 (10). Some initial
cycles of chemotherapy may be administered with reintroduction of three single cycles
(days 1-14) delivered at 3-month intervals later in the patient follow-up (e.g., months
9, 12, and 15).
The patients are questioned every 3 months concerning their well-being and the
extent of disturbance caused by treatment. These are compared to a baseline evalua-
tion obtained before the start of any adjuvant systemic treatment. Patients are requested
to give the same information one month after the first relapse. Linear Analogue Self
Assessments (LASA) (2;4) provide patient perceptions of adjustment/coping, phys-
ical well-being, mood, and appetite. A self-administered adjective checklist is also used
to evaluate general well-being at each assessment. These data will help to define values
of u, and ur that apply to a population of breast cancer patients.
CONCLUSION
The Q-TWiST methodology, which in this case has been applied to a breast cancer
trial of adjuvant therapies, can be extended to other fields which contain aspects of
value judgment for balancing symptoms of disease against toxic effects of treatment.
A major development in this methodology might be provided by refining the instru-
ments that help the patient to express his or her own perceptions of well-being.
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